These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Contraception.
    Author: Jones WR.
    Journal: Baillieres Clin Obstet Gynaecol; 1992 Sep; 6(3):629-40. PubMed ID: 1446424.
    Abstract:
    The principle of vaccination for the purposes of fertility regulation is scientifically elegant and socially compelling. Factors such as economic production, convenience of use, relatively long-lasting but reversible protection, low failure rate and the avoidance of mechanical devices or exogenous hormones make this approach a potentially attractive option for family planning programmes in both developing and developed countries. The major efforts in research and development have involved the prospect of active immunization against specific antigens of sperm, oocyte, zygote and early embryo, and the pregnancy hormone human chorionic gonadotrophin (hCG). Several anti-hCG vaccines have entered clinical trials. They operate by preventing or interrupting pregnancy at the peri-implantation stage probably by neutralizing the luteotrophic effect of hCG. The most refined vaccine is one directed against the unique C-terminal peptide on the beta-subunit of hCG. This vaccine provokes antibodies that are specific for hCG and do not cross-react with human luteinizing hormone (hLH). Preclinical studies in baboons and data from a phase I human trial indicate that this method is free of side-effects and provides the promise of a duration of effectiveness of up to 12 months. Future research will optimize the anti-hCG approach, utilize new vaccine delivery systems and broaden the spectrum of target antigens of potential utility for contraceptive vaccines. Theoretically, a vaccine for fertility regulation is possible. Family planning programs in developing and developed countries probably will find this fertility regulation approach attractive because of acceptability of the vaccine principle, large scale production at relatively low cost, convenience of use, relatively long-lasting but reversible protection, low failure rate, and the avoidance of mechanical devices or exogenous hormones. Research and development efforts revolve around the likelihood of active immunization against specific antigens of sperm, oocyte, zygote, and early embryo and the pregnancy hormone human chorionic gonadotropin (hCG). Some anti-hCG vaccines are already being tested in clinical trials. These vaccines likely negate the luteotrophic effect of hCG at the peri-implantation stage, resulting in pregnancy prevention. The most advanced anti-hCG vaccine targets the unique C-terminal peptide on the beta-subunit of hCG. It stimulates hCG specific antibodies and does not cross-react with human luteinizing hormone. Baboon studies and phase I human trials show that this advanced vaccine does not cause side-effects and may be effective for up to 1 year. Future research centers on improving the anti-hCG approach, use of new vaccine delivery systems, and expanding the spectrum of target antigens of potential utility for contraceptive vaccines.
    [Abstract] [Full Text] [Related] [New Search]